Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
This is a Phase Ib clinical trial to evaluate the efficacy and safety of AL2846 capsule in iodine-refractory differentiated thyroid cancer that has failed previous TKI treatment. The trial is planned to enroll 20 subjects. The trial is a single-arm, multi-center, open label clinical study. Objective response rate (ORR) is the primary endpoint.
Differentiated Thyroid Cancer
DRUG: AL2846 capsule
Objective remission rate (ORR), ORR is defined as the percentage of participants with complete remission (CR) and partial remission (PR) based on investigator records., From baseline up to 12 months.
Progression-free survival (PFS), PFS is defined as the time from randomization to the first recorded progressive disease (PD) or death from any cause., From baseline up to 12 months.|Disease control rate (DCR), DCR is defined as the percentage of patients who have achieved complete response, partial response and stable disease., From baseline up to 12 months.|Duration of remission (DoR), The time from the start of the first evaluation of the tumor as CR or PR to the first assessment as PD or death from any cause., From baseline up to 12 months.|Overall survival (OS), Time from the first administration to death due to any cause., From baseline to death event.|Occurrence of all adverse events (AEs), Adverse events are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0., From baseline to 28 days after the last dose or start of a new antineoplastic therapy (whichever comes first).
This is a Phase Ib clinical trial to evaluate the efficacy and safety of AL2846 capsule in iodine-refractory differentiated thyroid cancer that has failed previous TKI treatment. The trial is planned to enroll 20 subjects. The trial is a single-arm, multi-center, open label clinical study. Objective response rate (ORR) is the primary endpoint.